Business
Roche launches new PCR test to help improve diagnostic accuracy for women affected by vaginitis in countries following the CE Mark
The new PCR test aids in the diagnosis of infectious causes of vaginitis through the detection of bacteria associated with bacterial vaginosis and yeast associated with candida vaginitis. The test will help improve diagnostic accuracy for millions of women1 affected by vaginitis annually, delivering more accurate and specific results.This test offers faster diagnosis by using a single vaginal swab for broader sexual health testing, eliminating the need for an additional sample. Basel, 9 December
About this update from Roche Holding Ltd
[{"type":"image","alt":"F. Hoffmann-La Roche Ltd","displaySize":"","headline":null,"caption":"F. Hoffmann-La Roche Ltd","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":198,"url":"https://media.zenfs.com/en/globenewswire.com/d295bae68c32358ba6ac888e76c1cca2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/TdqKHuoAMRswPfW7YQ22wg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI3NztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/d295bae68c32358ba6ac888e76c1cca2","width":300,"height":198}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"The new PCR test aids in the diagnosis of infectious causes of vaginitis through the detection of bacteria associated with bacterial vaginosis and yeast associated with candida vaginitis. ","length":187,"tagName":"p"}]},{"val":[{"type":"text","content":"The test will help improve diagnostic accuracy for millions of women1 affected by vaginitis annually, delivering more accurate and specific results.","length":148,"tagName":"p"}]},{"val":[{"type":"text","content":"This test offers faster diagnosis by using a single vaginal swab for broader sexual health testing, eliminating the need for an additional sample.","length":146,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":481,"olType":false},{"type":"text","content":"Basel, 9 December 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the CE Mark for its cobas® BV/CV (Bacterial Vaginosis/Candida Vaginitis) assay to accurately identify specific bacteria and yeast responsible for BV and CV in vaginal samples from symptomatic patients collected using the cobas PCR Media proprietary tube.","length":330,"tagName":"p"},{"type":"text","content":"Clinicians typically rely on microscopy, pH testing, and clinical observation to diagnose BV and CV, which present with non-specific symptoms. These methods can deliver inaccurate results, leading to delays in treatment or prescription of unsuitable therapies. The cobas BV/CV assay resolves this challenge by delivering accurate and specific results, allowing healthcare professionals to deliver targeted therapies to patients more quickly.","length":441,"tagName":"p"},{"type":"text","content":"“The cobas BV/CV assay protects women from the risks of delayed or incorrect treatment, leading to faster relief from symptoms and a reduced likelihood of serious future com...